Blockade of P2X7 or activation of A2A present promising therapies for future GVHD treatment, but further studies in both allogeneic and humanised mouse models of this disease, as well as patients with GVHD, are required before these molecules can be targeted clinically. The gene discussed is IGKV2D-29; the disease is graft versus host disease.